地舒单抗治疗骨转移的疗效怎样呢？

On May 28, 2010, the European Commission approved the treatment of bone loss associated with hormone suppression in postmenopausal women with osteoporosis and prostate cancer. It can also be used in patients for whom other current treatments are ineffective or intolerable to reduce the risk of fractures.

Desosumab is a drug that targets the RANK ligand. Compared with bisphosphonates that have been clinically used for a long time, denosumab has the advantage of significantly prolonging the occurrence time of bone damage-related events. It can be administered subcutaneously in clinical practice and is easy to use.

What is the efficacy of denosumab in the treatment of bone metastases?

In a study analysis, James et al. evaluated the effect of denosumab and zoledronic acid in the treatment of bone-related events in prostate cancer bone metastases, showing that compared with zoledronic acid, denosumab can significantly reduce the risk of bone-related events. A large phase III clinical trial in the United States for patients with newly diagnosed multiple myeloma showed that compared with zoledronic acid, denosumab is not inferior in preventing skeletal-related events, can improve the survival rate of patients, significantly reduce renal toxicity, and has good economic benefits.

Giant cell tumor of bone typically occurs in adults between the ages of 20 and 40 years. In most cases, giant cell tumors of bone do not spread to other parts of the body, but they can impair normal bone growth, causing pain, limited range of motion, and fractures. Rarely, giant cell tumor of bone can transform into a malignant tumor and spread to the lungs. The launch of denosumab brings patients an innovative treatment option to control disease progression and improve quality of life.

On May 27, 2019, Amgen China announced that the injection has been approved by the National Medical Products Administration for the treatment of giant cell tumors of bone that are unresectable or that may result in severe functional impairment after surgical resection, including adults and adolescent patients with skeletal maturity (defined as at least 1 mature long bone and a body weight >45 kg).